T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice

F. Mc Allister, C. Steele, M. Zheng, E. Young, J. E. Shellito, L. Marrero and J. K. Kolls

*J Immunol* 2005; 175:3447; doi: 10.4049/jimmunol.175.5.3447-c

http://www.jimmunol.org/content/175/5/3447.3
CORRECTIONS


The word “apoptosis” was misspelled in the title, in the fourth sentence of the Abstract, in the first sentence of the third paragraph of the Introduction, and in the abbreviations list in Footnotes. The error has been corrected in the online version, which now differs from the print version as originally published.


In Results, in Fig. 7, the arrows indicating IL-4 and IFN-γ are inverted. The corrected figure is shown below.

![Corrected Figure](http://www.jimmunol.org/DownloadedFrom/fig7Corrected.png)

**In Results and Discussion**, after the first sentence in the last paragraph, the authors wish to add the sentences shown below. In **References**, the authors also wish to add the citation shown below.

Recently, Bielekova et al. described their findings concerning the induction of CD56<sup>bright</sup> NK cells by anti-IL2R therapy in multiple sclerosis patients (31). This is consistent with our observations in uveitis patients.


**In Disclosures**, a potential financial conflict of interest was inadvertently omitted. The disclosure shown below should have been declared.

R. A. B. Ezekowitz is cofounder and serves on the Board of Directors of NatImmune, a privately held biotechnology company.


The first author’s name is listed incorrectly. The correct name is Florencia McAllister.


The fifth author’s name is listed incorrectly. The correct name is John F. Elliott.